Pacific Shuanglin Bio-pharmacy (000403.SZ) Earnings Analysis
Pacific Shuanglin Bio-pharmacy (000403.SZ) next reports earnings on 2026-08-24, consensus EPS 0.24 CNY. Last quarter (2026-04-29) it missed with EPS 0.02 CNY vs 0.37 CNY est (-94.6%). It has beaten estimates in 1/4 recent quarters (25%). Trailing P/E 27.01.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 000403.SZ next report earnings?
| Next earnings date | 2026-08-24 |
|---|---|
| Consensus EPS estimate | 0.24 CNY |
| Revenue estimate | 0.34B |
000403.SZ earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-29 | 0.02 CNY | 0.37 CNY | -94.6% | Miss |
| 2025-10-29 | 0.1277 CNY | 0.24 CNY | -46.8% | Miss |
| 2025-08-22 | 0.15 CNY | 0.25 CNY | -40% | Miss |
| 2025-03-31 | 0.12 CNY | n/a | n/a | n/a |
| 2024-10-27 | 0.3 CNY | 0.29 CNY | +3.4% | Beat |
Beat rate: 1/4 (25%) over reported quarters with consensus data.
000403.SZ valuation and analyst view
| Trailing P/E | 27.01 |
|---|---|
| Trailing EPS | 0.3075 CNY |
| Price / book | 1.37 |
| Dividend yield | 0.00% |
| Market cap | 9.10B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Pacific Shuanglin Bio-pharmacy (000403.SZ)'s next earnings date?
Pacific Shuanglin Bio-pharmacy is next scheduled to report on 2026-08-24, with a consensus EPS estimate of 0.24 CNY and revenue estimate of 0.34B.
Did 000403.SZ beat earnings last quarter?
In its 2026-04-29 report, 000403.SZ posted EPS of 0.02 CNY versus a 0.37 CNY estimate — a miss of 94.6%.
What is 000403.SZ's earnings track record?
Over the last 4 reported quarters with consensus data, 000403.SZ beat estimates 1 times (25%).
What is 000403.SZ's current P/E ratio and EPS?
000403.SZ trades at a trailing P/E of 27.01 on trailing EPS of 0.3075001615667617 CNY.
What do analysts rate 000403.SZ?
000403.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.